Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback